JNJ Stock Surges on FDA Approval and Expanded Cancer Treatment Use

Johnson & Johnson's stock price rose after the company secured U.S. FDA approval for Imaavy in warm autoimmune hemolytic anemia treatment.

The treatment now covers patients aged 12 years and older with the condition, which is characterized by severe anemia, fatigue, blood clots, and kidney complications.

Imaavy works by blocking a protein that supports antibody activity in the bloodstream, reducing harmful antibodies while maintaining broader immune functions.

The treatment was approved following a study involving 115 adults during mid-to-late stage clinical development, which showed stronger lasting improvements in hemoglobin levels among patients receiving Imaavy compared to those receiving placebo treatment.

In related news, Johnson & Johnson also received approval from the European Commission for Tecvayli's expanded application, allowing its use with daratumumab to treat adults with relapsed or refractory multiple myeloma.

The company's pharmaceutical business continues to grow through new approvals and treatment developments in immunology, oncology, and rare disease medicines.